May 22, 2014 American Society
for Gene and Cell Therapy Annual Meeting, Washington, DC Phase I Clinical Trial of Human Embryonic Stem Cell - Derived Oligodendrocyte Progenitors in Patients with Neurologically Complete Thoracic Spinal Cord Injury: Results and Next Steps
Caribou recently cofounded Intellia Therapeutics for the development of
human gene and cell therapies based on their proprietary CRISPR - Cas9 technology platform.
Molecular Therapy is the leading journal for
gene and cell therapy research, publishing important peer - reviewed research and cutting - edge reviews and commentaries.
New technologies such
as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.
Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of
Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy.
American Society of
Gene and Cell Therapy Annual Meeting Speaker: Olivia Kelly, Ph.D., Senior Director, Cell Biology Presentation: Developing a Cell Therapy Combination Product for Diabetes Date / Time: May 16, 8:30 AM EDT Location: Hilton Chicago, Chicago
Overall, SR - Tiget represents a multi-disciplinary research environment, which provides a unique blend of scientific expertise in the development of innovative
gene and cell therapy strategies, access to relevant preclinical models to evaluate their efficacy and safety, as well as competence in conducting early phase clinical trials.
As Barrie Carter, former president of the American Society of
Gene and Cell Therapy recently told Xconomy, «Everyone in the Society realizes we have to start thinking about [pricing].
Our results provide proof of principle for using transcription factor - induced reprogramming combined
with gene and cell therapy for disease treatment in mice.
This group is working towards the identification of the genetic bases and the pathophysiological processes underlying PIDs and autoimmune / autoinflammatory diseases with the goal of developing novel ex
vivo gene and cell therapy strategies for such conditions.
Intellia has exclusive access to Caribou's CRISPR - Cas9 technology for the development of new
human gene and cell therapies as well as anti-viral therapies.
GLP Test Facilities combine skills and expertise
in gene and cell therapy research, pharmaceutical research and development, pathology and quality assurance.
Drs. Jean Bennett, Luk Vandenberghe, Luca Biasco, and Francesca Pasinelli will be recognized for their tremendous contributions to
gene and cell therapy at ASGCT's 21st Annual Meeting.
EC was supported by the Else Kröner - Fresenius - Stiftung, the Excellence Cluster Cardiopulmonary System (DFG; Exc147 - 1), the German Centre for Cardiovascular Research (BMBF) and the LOEWE Center
for Gene and Cell Therapy (Hessen, Germany).
«Our results are promising because they show that a combination
of gene and cell therapy can improve the outcome in the case of critical limb ischemia associated with aging or diabetes,» says Semenza.
Intellia is developing human
gene and cell therapies for both ex vivo and in vivo applications using CRISPR - Cas9 gene editing technology.
He was awarded a European Research Council Advanced Investigator Grant (ERC) in 2009, the Outstanding Achievement Award from the American Society of
Gene and Cell Therapy (ASGCT) in 2014 and from ESGCT in 2015, an Honorary doctorate from the Vrije University, Brussel, in 2015, the Jimenez Diaz Prize in 2016, and the Beutler Prize from the American Society of Hematology (ASH) in 2017.
Caribou has provided Intellia with an exclusive license to utilize its technology platform for the discovery, development, and com ¬ mercialization of human
gene and cell therapies.
In 2014, Caribou co-founded Intellia Therapeutics, which is utilizing Caribou's technology platform in the discovery, development and commercialization of human
gene and cell therapies.
He is Member of the European Molecular Biology Organization (EMBO), has been President of the European Society of
Gene and Cell Therapy (ESGCT), and has been appointed as expert on the «Human Gene Editing Study» of the US National Academies of Sciences and of Medicine, and on the Italian National Committee for Biosafety, Biotechnology and Life Sciences.
Data from this trial was previously presented at World Advanced Therapies and Regenerative Medicine (May 17 - 19,2017; London, UK) and the 20th Annual Meeting American Society of
Gene and Cell Therapy (ASGCT, May 10 - 13, 2017; DC, USA).
The American Society of
Gene and Cell Therapy (ASGCT) Symposium Immunologic Responses to Gene Therapy for Hemophilia Saturday, May 5, 10:15 AM — 12:15 PM, Room 19AB Chairs: Federico Mingozzi, INSERM, Univ. of Pittsburgh Med.
Therapeutic strategies aiming at restoring the function of the implicated genes (
gene and cell therapies) are very encouraging but not applicable in a near future to the variety of MDs.
Dr. Theodore Friedmann, professor of pediatrics at the University of California - San Diego Medical Center and the former president of the American Society of
Gene and Cell Therapy, was a gene therapy pioneer.
Gene and cell therapies have made important medical advances over the past three decade, developing technologies and testing novel therapies in multiple human clinical trials of many diseases.
ASGCT is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in
gene and cell therapy.
The Society's mission is to advance knowledge, awareness, and education leading to discovery and clinical application of
gene and cell therapies to alleviate disease.
ASGCT's annual meeting is the essential scientific conference for professionals in
gene and cell therapy.
ASGCT is your unbiased source for reliable, scientific information, news, and breakthroughs in
gene and cell therapy.
The San Raffaele Telethon Institute for Gene Therapy (SR - Tiget) was created in 1995 as a joint venture between the Telethon Foundation and IRCCS Ospedale San Raffaele, with the mission to perform cutting - edge research in
gene and cell therapy and to translate its results into therapeutic advances, focusing on genetic diseases.
European Society of
Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, exchange of information and technology.
Dr. Nixon is a Diplomate of the American College of Veterinary Surgeons, and a current or past member of the American Association of Equine Practitioners, the Veterinary Orthopedic Society, the Orthopedic Research Society, the International Cartilage Repair Society, and American Society for
Gene and Cell Therapy.
Clients routinely benefit from Hemmie's strategic business perspective and legal acumen from her two - plus decades of experience within the bio pharmaceutical, medical device,
gene and cell therapy and genomics sectors.